) The University of Colorado Comprehensive Cancer Center (UCCC) is the only NCI- designed comprehensive Cancer Center in the Rocky Mountain region which has a population of about 8 million. The goals are to: 1) contribute to the reduction and elimination of cancer as a human health problem through coordinated programs in basic, clinical, translational and population sciences and 2) provide the citizens of the Rocky Mountain region with state-of-the-art cancer research, clinical, prevention and control and education programs. There are 244 full and 82 associate members who participate in one or more of the UCCC's 10 program including Cell Biology, Molecular and Structural Biology, Immunology and Immunotherapy, Hormone Related Malignancies, Tobacco Related Malignancies, Developmental Therapeutics, Pediatric Oncology, Cancer Genetics, Carcinogenesis and Chemoprevention and Clinical and Community Cancer Prevention and Control. Over the past 5 years, programs were reorganized to foster collaborative and translational research by including elements of basic, clinical and population sciences into the programs and to respond to rapid changes in scientific technology. UCCC members' productivity has increased as documented by more grant funding (32%), by a phenomenal growth in accruals to clinical trials (>1000%) and by their publication record. Cancer focus also increased as shown by the increases in NCI and peer-reviewed cancer agency funding (36%), and the increase in cancer clinical trials noted above. The research of the members is supported by 15 shared core resources which include 4 new facilities (Gene Expression, NMR, Pharmacology, Survey Research), 9 cores with expanded services (Biostatistics, Clinical Investigations, Cytogenetics, Flow Cytometry, Laboratory Animals, Tissue Procurement, Radiological Sciences, Protein Microchemistry, and Transgenic/Knockout) and 2 cores with continued services utilized by increased number of members (DNA Sequencing and Tissue Culture/Monoclonal Antibody). Core usage has increased over the past 5 years as documented by number of members, units of use, and charge back fees generated (110% increase). We have emphasized new technologies in the creation and expansion of these services. The UCCC is a """"""""matrix"""""""" Center within the School of Medicine, but has members from all of the UCHSC schools and affiliated institutions. During the next 3 years the UCCC will relocate to the new Fitzsimons campus which will triple the available outpatient and clinical research space (Nov. 2000) and the basic research space (Nov. 2002) at a cost of more than $180 million.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-14
Application #
6229847
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1988-03-01
Project End
2006-01-31
Budget Start
2001-07-23
Budget End
2002-01-31
Support Year
14
Fiscal Year
2001
Total Cost
$3,278,759
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Shearn, Colin T; Pulliam, Casey F; Pedersen, Kim et al. (2018) Knockout of the Gsta4 Gene in Male Mice Leads to an Altered Pattern of Hepatic Protein Carbonylation and Enhanced Inflammation Following Chronic Consumption of an Ethanol Diet. Alcohol Clin Exp Res 42:1192-1205
Giles, Erin D; Jindal, Sonali; Wellberg, Elizabeth A et al. (2018) Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res 20:50
Nemkov, Travis; Sun, Kaiqi; Reisz, Julie A et al. (2018) Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage. Haematologica 103:361-372
Soontararak, Sirikul; Chow, Lyndah; Johnson, Valerie et al. (2018) Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model. Stem Cells Transl Med 7:456-467
Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98
Ross, Brian C; Boguslav, Mayla; Weeks, Holly et al. (2018) Simulating heterogeneous populations using Boolean models. BMC Syst Biol 12:64
Wang, Guankui; Benasutti, Halli; Jones, Jessica F et al. (2018) Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles. Colloids Surf B Biointerfaces 161:200-209
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550

Showing the most recent 10 out of 1634 publications